Home >> Proteins >> Viral Antigens

Viral Antigens(病毒抗原)

A viral Antigen is an antigen with multiple antigenicities that is protein in nature, strain-specific, and closely associated with the virus particle. A viral antigen is a protein encoded by the viral genome.A viral protein is an antigen specified by the viral genome that can be detected by a specific immunological response.

Viruses are infectious pathogens that cause serious diseases & major threats for global public health, such as influenza, hepatitis, & AIDS. Virus is a sub-micrometer particle that has DNA or RNA packed in a shell called capsid. Viral antigens protrude from the capsid and often fulfill important function in docking to the host cell, fusion, and injection of viral DNA/RNA. Antibody-based immune responses form a first layer of protection of the host from viral infection; however, in many cases a vigorous cellular immune response mediated by T-cells and NK-cells is required for effective viral clearance. When cellular immunity is unable to clear the virus, the infection can become chronic, and serum antibodies to the viral pathogen are used as first indicator for the diagnosis of the disease.

ELISAs provide a valuable tool in the detection and diagnosis of virus infection. The ability to produce recombinant viral proteins will ensure that future ELISAs are safe, specific and rapid. Even when a virus cannot be cultured, provided gene sequence is available, it is possible to rapidly respond to emerging viruses and new viral strains of existing pathogens.

Recombinant viral antigens contain part of viral sequence meaning that the recombinant antigen contains a region which can be recognized by different antibodies produced by different individuals. This reduces the risk of false negatives which can occur with synthetic peptides, which contain only a small portion of the entire protein. If an individual infected with a viral antigen makes antibodies to a part of the protein not included in the synthetic peptides, a false negative results.

Recombinant viral protein usually contains a fusion protein/partner which produces superior attachment to assay surfaces such as wells. For this reason, smaller amounts of recombinant protein will produce the same results as larger amounts of unfused protein. The choice of fusion partner prevents false positives, allowing superior adhesion without incorrect results.

Recombinant Viral proteins are expressed in bacteria, yeast, mammalian cells, and viruses. E. Coli cells were first to be used for this purpose but the expressed proteins were not glycosylated, which was a major drawback since many of the immunogenic proteins of viruses such as the envelope glycoproteins, were glycosylated. Nevertheless, in many instances, it was demonstrated that the non-glycosylated protein backbone was just as immunogenic. The obvious advantage of recombinant viral antigens is that they are available in unlimited quantities and the production and quality control processes is simple.

Advantages of defined using recombinant viral antigens:
1. Production and quality control is simple.
2. No nucleic acids or other viral or external proteins, therefore less toxic.
3. Safer in cases where viruses are oncogenic or establish a persistent infection.
4. Feasible even if virus cannot be cultivated

Disadvantages:
1. May be less immunogenic than conventional inactivated whole-virus vaccines.
2. Requires adjuvant .
3. Fails to elicit CMI.

Facts about Viral Antigens:
1. A Viral Protein Mimics its Way into cells.
2. Viral Protein Helps Infected T Cells Stick To Uninfected Cells.
3. The Viral Protein A238L Inhibits Cyclooxygenase-2 Expression through a Nuclear Factor of Activated T Cell-dependent Trans-activation Pathway.
4. Viral Protein is an effective preventative against ear infection.
5. HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore.
6. The Level of Viral Antigen Presented by Hepatocytes Influences CD8 T-Cell Function.
7. Antigen-presenting cells from calves persistently infected with bovine viral diarrhea virus, a member of the Flaviviridae, are not compromised in their ability to present viral antigen.
8. There is a difference in the distribution and spread of a viral antigen, development of lesions and correlation between presence of viral antigen and lesions.
9. The absence of viral antigens on the surface of equine herpesvirus-1-infected peripheral blood mononuclear cells is a strategy to avoid complement-mediated lysis.
10. Viral Protein Influences Key Cell-signaling Pathway.
11. A viral protein produced by cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.
12. Protection by recombinant viral proteins against a respiratory virulent avian metapneumovirus has been achieved.
13. Viral O-acetylesterases are found in influenza C viruses and Corona-viruses. Viral O-acetylesterases remove cellular receptors from the surface of target cells which destroys the receptor. Recombinant viral O-acetylesterases derived from Sf9 insect cells as chimeric proteins fused to eGFP specifically hydrolyze 9-O-acetylated sialic acids, while that of sialodacryoadenitis virus, a rat coronavirus related to mouse hepatitis virus, is specific for 4-O-acetylated sialic acid. The recombinant esterases were shown to specifically de-O-acetylate sialic acids on glycoconjugates. The recombinant viral proteins can be used to unambiguously identify O-acetylated acids.

Products for  Viral Antigens

  1. Cat.No. 产品名称 Information
  2. GP26390 CoV-2-S1 The HEK293 derived recombinant protein contains the Novel Coronavirus 2019-nCoV Spike Glycoprotein S1, Wuhan-Hu-1 strain, amino acids 1-674 fused to Fc tag at C-terminal
  3. GP26389 SARS Spike (14-1195) SARS Spike produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 1188 amino acids (14-1195 aa) and having a molecular mass of 131
  4. GP26388 SARS Spike (306-515), Sf9 SARS Spike produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 219 amino acids (306-515 aa) and having a molecular mass of 24
  5. GP26387 SARS Spike (306-515) The recombinant SARS Spike containing a total of 220 amino acids (306-515) and having a calculated Mw of 24
  6. GP26386 SARS Spike (306-527) The HEK293 derived recombinant protein contains the SARS Coronavirus spike S glycoprotein Receptor Binding Domain, amino acids 306-527 fused to His tag at C-terminal
  7. GP26385 SARS Spike (14-667) The HEK293 derived recombinant protein contains the SARS Coronavirus Spike S1 Gycoprotein, amino acids 14-667 fused to His tag at C-terminal
  8. GP26384 SARS Spike (1-666) The HEK293 derived recombinant protein contains the SARS Coronavirus Spike S1 Gycoprotein, amino acids 1-666 fused to His tag at C-terminal
  9. GP26383 SARS Spike Mosaic The E
  10. GP26382 SARS Spike (408-470, 540-573) The E
  11. GP26381 SARS Spike (1-53, 90-115, 171-205) The E
  12. GP26380 SARS Membrane The E
  13. GP26379 SARS Nucleocapsid (340-390), His The E
  14. GP26378 SARS Nucleocapsid, 1-49 a.a. The E
  15. GP26377 SARS Envelope, His The E
  16. GP26376 CoV OC43 Human Recombinant Human Coronavirus OC43 Nucleoprotein is full length protein except the predicted signal peptide of the first 30 aa produced in E
  17. GP26375 CoV HKU1 Human Recombinant Human Coronavirus HKU1 Nucleoprotein is full length protein except the predicted signal peptide of the first 30 aa produced in E
  18. GP26374 SARS MERS RBD SARS MERS RBD Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 258 amino acids (358-606 aa) and having a molecular mass of 28
  19. GP26373 SARS MERS S2 SARS MERS S2 Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 554 amino acids (752-1296aa) and having a molecular mass of 60
  20. GP26372 SARS MERS, (18-751) SARS MERS Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 740 amino acids (18-751aa) and having a molecular mass of 82
  21. GP26371 SARS MERS, Sf9 SARS MERS Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 1285 amino acids (18-1296aa) and having a molecular mass of 141
  22. GP26370 SARS MERS, HEK The HEK293 derived recombinant protein contains the SARS MERS Spike Glycoprotein S1, amino acids 18-725 fused to dimeric Fc tag at N-terminal having a total Mw of 215
  23. GP26369 SARS Nucleocaspid (2-422), HEK The HEK293 derived recombinant protein contains the SARS Coronavirus Nucleoprotein, amino acids 2-422 fused to a 6 His tag at N-terminal
  24. GP26307 M.Pneumoniae P30 M
  25. GP26118 ACE2 (18-740) Human, Biotin The HEK293 derived ACE2 Human recombinant biotinylated protein contains the amino acids Gln 18-Ser 740 fused to His-AVI tag at C-terminal having a predicted Mw of 87
  26. GP26117 ACE2 (18-740) Human, Fc The HEK293 derived ACE2 Human recombinant protein contains the amino acids 18-740 fused to Fc tag at C-terminal
  27. GP26116 ACE2 (18-740) Human The HEK293 derived ACE2 Human recombinant protein contains the amino acids 18-740 fused to IgG-His tag ( 242 a
  28. GP26115 ACE2 (19-740) Human TheCHOderived ACE2 Human recombinant protein contains theextracellular domain amino acids 19-740 fused to Fc tag at C-terminal
  29. GP26114 ACE2 (18-615) Human The CHO derived ACE2 Human recombinant protein contains the extracellular domain amino acids 18- 615 fused to Fc tag at C-terminal and has a molecular weight of ~130 kDa
  30. GP26113 ACE Human ACE Human produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 1235 amino acids (30-1256 a
  31. GC26066 WAY-383487 WAY-383487 is one of the Tat peptide derivatives and inhibits HIV-1 long terminal repeat-activated transcription.
  32. GC25306 CQ31 CQ31, a small molecule, selectively activates caspase activation and recruitment domain-containing 8 (CARD8).
  33. GC68449 CA inhibitor 1

    GS-6207 analog

    CA inhibitor 1 (GS-6207 analog) 是一种有效的 HIV 衣壳抑制剂,可用于抑制 HIV。
  34. GC68023 HIV-1 inhibitor-48 HIV-1 inhibitor-48 (compound 13o) 是一种新型的非核苷逆转录酶抑制剂 (NNRTI),具有抗 HIV-1 活性。
  35. GC52475 Zanamivir-13C,15N2 (hydrate) An internal standard for the quantification of zanamivir
  36. GC52326 Biotin-PEG4-LL-37 (human) (trifluoroacetate salt) A biotinylated and pegylated form of LL-37
  37. GC66467 Claficapavir

    A1752

    Claficapavir (A1752) 是一种特异的核衣壳蛋白 (nucleocapsid protein) 抑制剂,IC50 约为1μM。Claficapavir 与 HIV-1 NC(Kd=20 nM) 强烈结合,从而抑制 NC 的伴侣特性,并导致对 HIV-1 具有良好的抗病毒活性。
  38. GC66051 Cabotegravir sodium

    卡博特韦钠; GSK-1265744 sodium; S/GSK1265744 sodium

    An HIV-1 integrase inhibitor
  39. GC65963 AzddMeC

    CS-92

    AzddMeC (CS-92) 是一种抗病毒核苷类似物,也是一种有效的,选择性的,具有口服活性的 HIV-1 逆转录酶和 HIV-1 复制的抑制剂。在感染 HIV-1 的人类 PBM 细胞和感染 HIV-1 的人类巨噬细胞中,AzddMeC 的 EC50 值分别为 9 nM 和 6 nM。
  40. GC65905 NBD-14189 NBD-14189 是一种有效的 HIV-1 进入拮抗剂,对 HIV-1HXB2 假病毒的 IC50 为 89nM。NBD-14189 与 HIV-1 gp120 结合并显示出强大的抗病毒活性 (EC50<200 nM)。
  41. GC65903 NBD-14270 NBD-14270,一种吡啶类似物,是一种有效的 HIV-1 进入拮抗剂,对 50 株 HIV-1 假型病毒的 IC50 为 89 nM。NBD-14270 与 HIV-1 gp120 结合并显示出强大的抗病毒活性 (EC50<200 nM)。NBD-14270 显示低细胞毒性 (CC50>100 μM)。
  42. GC52191 Deacetylanisomycin

    脱乙酰茴香霉素

    A derivative of anisomycin
  43. GC52174 Sulfadoxin-d4

    磺胺邻二甲氧嘧啶-D4,Sulphadoxine-d4

    An internal standard for the quantification of sulfadoxin
  44. GC52171 Clindamycin-d3 (hydrochloride)

    克林霉素-D3盐酸盐

    An internal standard for the quantification of clindamycin
  45. GC65363 (1R)-Tenofovir amibufenamide

    (1R)-HS-10234

    (1R)-Tenofovir amibufenamide ((1R)-HS-10234) 是 Tenofovir amibufenamide 的异构体,是一种口服活性抗病毒药物。(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 是一个 HIV 病毒感染的抑制剂和乙型肝炎病毒的抑制剂 ( HBV )。(1R)-Tenofovir amibufenamide ((1R)-HS-10234) 可用于 HIV 感染、乙肝研究。
  46. GC65256 HIV-1 inhibitor-6 HIV-1 inhibitor-6 (compound 9) 是一种基于二杂芳基酰胺的化合物,是一种有效的 HIV-1 pre-mRNA 选择性剪接抑制剂。HIV-1 inhibitor-6 可以阻断 HIV 复制。HIV-1 inhibitor-6 对野生型 HIV-1IIIB (亚型 B,X4-tropic) 和 HIV-1 97USSN54 (亚型 A,R5-tropic) 具有活性,EC50 值分别为 0.6 μM 和 0.9 μM。HIV-1 inhibitor-6 抑制对靶向 HIV 逆转录酶、蛋白酶、整合酶和辅助受体 CCR5 的药物耐药的 HIV 菌株,EC50 范围为 0.9 至 1.5 μM。
  47. GC65158 HIV-1 inhibitor-8 HIV-1 inhibitor-8 是一种具有口服活性、低毒和有效的 HIV -1 非核苷逆转录酶抑制剂 (NNRTI)。HIV-1 inhibitor-8 对各种 HIV -1 菌株产生有效的抗病毒活性 (EC50=4.44~54.5 nM)。HIV-1 inhibitor-8 对 WT HIV-1 逆转录酶的 IC50 为 0.081 μM。
  48. GC65134 HIV-IN-6 HIV-IN-6 是一种 HIV-Ⅰ 病毒复制抑制剂,通过靶向与病毒 Nef 蛋白相互作用的 Src 家族激酶 (SFK) (如 Hck) 而起作用。
  49. GC65085 3'-Azido-3'-deoxy-5-methylcytidine 3'-Azido-3'-deoxy-5-methylcytidine (CS-92) 是一种有效的异嗜性小鼠白血病相关逆转录病毒 (XMRV) 抑制剂,作用于 MCF-7 细胞,CC50 为 43.5 μM。3'-Azido-3'-deoxy-5-methylcytidine (CS-92) 作用于外周血单核细胞 (PBM),抑制 HIV-1 逆转录酶,EC50 为 0.06 μM。
  50. GC65034 Ibalizumab

    伊巴组单抗,TMB-355; TNX-355

    Ibalizumab (TMB-355) 是一种人源化 IgG4 单克隆抗体,通过与 CD4 受体结合来阻止 HIV 细胞进入。Ibalizumab 具有用于 HIV-1 感染研究的潜力。
  51. GC64484 Emivirine

    MKC-442

    Emivirine (MKC-442) 是有效的非核苷逆转录酶的抑制剂 (NNRTIs),对dTTP 和 dGTP 依赖性 DNA 或 RNA 聚合酶活性的 Ki 值分别为 0.20 和 0.01 μM。Emivirine 具有有效且选择性的抗 HIV-1 活性。

Items 101 to 150 of 719 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction